Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage pharmaceutical company headquartered in Dublin, Ireland. The company focuses on developing differentiated anti-infectives to combat the global crisis of multi-drug resistant pathogens, aiming to improve outcomes for patients with serious and life-threatening infectious diseases. Its lead product, ORLYNVAH (oral sulopenem), is the first and only approved oral penem, indicated for treating uncomplicated urinary tract infections (uUTIs) caused by designated microorganisms such as Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibiotic options. Sulopenem, a novel penem anti-infective, demonstrates potent in vitro activity against a broad spectrum of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Iterum is also advancing an intravenous formulation of sulopenem. Through these innovations, Iterum Therapeutics plc addresses critical unmet needs in the anti-infective market, particularly for infections where treatment options are scarce.